Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer.

about

Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer.

Item

http://www.wikidata.org/entity/Q55286232

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Phase I study of third-line pa ...... litaxel for pancreatic cancer.

@en

Phase I study of third-line pa ...... litaxel for pancreatic cancer.

@nl

type

Item

label

Phase I study of third-line pa ...... litaxel for pancreatic cancer.

@en

Phase I study of third-line pa ...... litaxel for pancreatic cancer.

@nl

prefLabel

Phase I study of third-line pa ...... litaxel for pancreatic cancer.

@en

Phase I study of third-line pa ...... litaxel for pancreatic cancer.

@nl

P1476

Phase I study of third-line pa ...... litaxel for pancreatic cancer.

@en

P2093

Hidehiro Tajima

http://www.w3.org/2001/XMLSchema#string

Hironori Hayashi

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Takamura

http://www.w3.org/2001/XMLSchema#string

Isamu Makino

http://www.w3.org/2001/XMLSchema#string

Itasu Ninomiya

http://www.w3.org/2001/XMLSchema#string

Jun Kinoshita

http://www.w3.org/2001/XMLSchema#string

Katsunobu Oyama

http://www.w3.org/2001/XMLSchema#string

Keishi Nakamura

http://www.w3.org/2001/XMLSchema#string

Koichi Okamoto

http://www.w3.org/2001/XMLSchema#string

Masafumi Inokuchi

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan

Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer.

Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-beta/Smad activity.

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications.

Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report.

P304

523-527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2018.1579

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29556385

http://www.w3.org/2001/XMLSchema#string

P932

5844031

http://www.w3.org/2001/XMLSchema#string